{
  "symbol": "BMEA",
  "company_name": "Biomea Fusion Inc",
  "ir_website": "https://investors.biomeafusion.com/",
  "structured_data": [
    {
      "section_name": "Financial Reports",
      "links": [
        {
          "title": "Biomea Fusion Corporate Presentation Q4 2024",
          "url": "https://investors.biomeafusion.com/static-files/c13b5886-3c81-4546-a799-181f8c05e0ac",
          "content": "\n"
        }
      ]
    },
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://investors.biomeafusion.com/news-events/press-releases",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  Press Releases \n\n#  Press Releases \n\n[Investor Menu](investors.html#)\n\nYear None2024202320222021\n\n2024\n\nNov 18, 2024 \n\n[Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)](/news-releases/news-release-details/late-breaker-oral-presentation-showing-new-analysis-escalation)\n\nIcovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2 Diabetes Patients Characterized by Insulin Deficiency 32 patients from the 100mg and 200mg cohorts, doses selected for the expansion phase, were characterized based on baseline biomarkers \n\nNov 01, 2024 \n\n[Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-1)\n\nREDWOOD CITY, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of oral covalent small molecules to treat and improve the lives of patients with diabetes, \n\nOct 30, 2024 \n\n[Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate](/news-releases/news-release-details/biomea-fusion-presents-preclinical-data-showing-icovamenib-bmf)\n\nPreclinical data from ex vivo human islet experiments showed that icovamenib (BMF-219) was able to enhance the activity of glucagon-like peptide-1 (GLP-1)-based therapies, potentially leading to increased insulin secretion and improved glycemic control in patients with diabetes Phase II study \n\nOct 29, 2024 \n\n[Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights](/news-releases/news-release-details/biomea-fusion-reports-third-quarter-2024-financial-results-and)\n\nU.S. Food and Drug Administration (FDA) lifted Clinical Hold on COVALENT-111 (Type 2 Diabetes) & COVALENT-112 (Type 1 Diabetes) trials COVALENT-111 Phase 2b 26-week topline data of the dose expansion cohorts expected in December 2024 COVALENT-112 Phase 2a 26-week topline data of the open label \n\nOct 21, 2024 \n\n[Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219](/news-releases/news-release-details/biomea-fusion-announces-approval-icovamenib-international)\n\nIcovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells REDWOOD CITY, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company \n\nOct 15, 2024 \n\n[Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy](/news-releases/news-release-details/biomea-fusion-host-conference-call-and-webcast-wednesday-october)\n\nREDWOOD CITY, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with diabetes, obesity, and genetically \n\nOct 07, 2024 \n\n[Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)](/news-releases/news-release-details/biomea-fusion-present-1st-annual-asian-conference-innovative)\n\nBMF-219 is an investigational oral covalent menin inhibitor developed to regenerate insulin-producing beta cells Two trial-in-progress oral presentations to feature Phase II study design of oral covalent menin inhibitor BMF-219 in patients with type 2 diabetes (COVALENT-111) and in patients with \n\nOct 01, 2024 \n\n[Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts](/news-releases/news-release-details/biomea-announces-formation-global-scientific-advisory-board-22)\n\nInternational diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s evolving pipeline REDWOOD CITY, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. \n\nSep 26, 2024 \n\n[FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials](/news-releases/news-release-details/fda-lifts-clinical-hold-bmf-219-type-2-and-type-1-diabetes)\n\nREDWOOD CITY, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to treat and improve the lives of patients with metabolic \n\nAug 01, 2024 \n\n[Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)](/news-releases/news-release-details/biomea-fusion-inc-reports-inducement-grant-under-nasdaq-0)\n\nREDWOOD CITY, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent small molecules to treat patients with metabolic diseases and genetically defined \n\nDisplaying 1 - 10 of 23 \n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        }
      ]
    },
    {
      "section_name": "Investor Resources",
      "links": [
        {
          "title": "Inquiries",
          "url": "https://investors.biomeafusion.com/ir-resources/investor-contact",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  Investor Contact \n\n#  Investor Contact \n\n[Investor Menu](investors.html#)\n\n**Investor Relations Contact**\n\nChunyi Zhao Head of Investor Relations IR@biomeafusion.com czhao@biomeafusion.com (650) 460-7759\n\nName\n\nEmail\n\nSubject\n\nComments\n\nLeave this field blank\n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        },
        {
          "title": "Investor FAQs",
          "url": "https://investors.biomeafusion.com/ir-resources/investor-faqs",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  Investor FAQs \n\n#  Investor FAQs \n\n[Investor Menu](investors.html#)\n\n[Show All](#)\n\nWhat is Biomea Fusion’s official name?\n\nBioMea Fusion, Inc.\n\nWhere is Biomea Fusion’s corporate headquarters?\n\nBiomea Fusion is headquartered at 900 Middlefield Road, 4th Floor, Redwood City, CA 94063. The main phone number is 650-980-9099.\n\nWhen was Biomea Fusion founded?\n\nBiomea Fusion was founded in August 2017.\n\nWhere is Biomea Fusion incorporated?\n\nBiomea Fusion is incorporated in the state of Delaware.\n\nWhen did Biomea Fusion go public?\n\nBiomea Fusion began trading common stock shares on the NASDAQ Global Market as “BMEA” on April 16, 2021.\n\nHow is Biomea Fusion’s stock traded?\n\nBiomea Fusion is traded on the NASDAQ Global Market under the ticker symbol BMEA and its CUSIP number is 09077A 106.\n\nWhen is Biomea Fusion’s fiscal year-end?\n\nBiomea Fusion’s fiscal year-end is on December 31.\n\nWho is Biomea Fusion’s transfer agent?\n\nCommunication regarding transfer requirements, lost certificates and changes of address should be directed to: American Stock Transfer & Trust Company, LLC (AST) help@astfinancial.com (800) 937-5449 or (718) 921-8124 \n\n  * Teletypewriter for the hearing impaired:\n  * (866) 703-9077\n  * (718) 921-8386\n\n\n\nWho is Biomea Fusion’s legal counsel?\n\nLatham & Watkins, LLP 140 Scott Drive Menlo Park, CA 94025\n\nWho are Biomea Fusion’s independent auditors?\n\nDeloitte & Touche, LLP 555 Mission Street San Francisco, California 94105\n\nWhere can I get the latest corporate news releases and financial reports?\n\nBiomea Fusion’s press release archives can be viewed [here](/news-events/press-releases).\n\nHow can I view documents Biomea Fusion has filed with the Securities & Exchange Commission (SEC), including Forms 10-K and 10-Q? \n\nBiomea Fusion’s SEC filings can be viewed [here](/financial-information/sec-filings).\n\nWho should I contact if I have further questions?\n\nYou can submit queries to ir@biomeafusion.com.\n\nHow can I sign up to receive Biomea Fusion’s press releases and other company news?\n\nPlease select the ‘Email Alerts’ icon in the Investor Relations section of our website to be added to the Biomea Fusion distribution list.\n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://investors.biomeafusion.com/ir-resources/email-alerts",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  Email Alerts \n\n#  Email Alerts \n\n[Investor Menu](investors.html#)\n\nRequired fields denoted by an asterisk ().\n\nHide lower priority columns\n\nAlert type  \n---  \nQuote  \nSEC Filing  \nEvent  \nNews  \nWeekly Summary  \n  \nEmail\n\nLeave this field blank\n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings & Financials",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://investors.biomeafusion.com/financial-information/sec-filings",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  SEC Filings \n\n#  SEC Filings \n\n[Investor Menu](investors.html#)\n\nGroup 3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year - Any -2024202320222021\n\n- Any -\n\nItems per page 102550\n\n10\n\n[Filing date ](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"sort by Filing date\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"sort by Description\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"sort by Form\") | View  \n---|---|---|---  \nNov 12, 2024 | An amendment to the SC 13G filing | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0001085146-24-005527) |  [0001085146-24-005527.pdf](/static-files/6688edfc-ed8f-4d2a-8cdf-057313fae366) [0001085146-24-005527.rtf](/static-files/263b4e15-e2ad-4175-8bcc-f9ed657f1eb7) [0001085146-24-005527.xls](/static-files/cbee189c-f594-49f9-bb9d-11145bffcdc0) [View HTML](/node/9051/html)  \nOct 31, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001193125-24-248083) |  [0001193125-24-248083.pdf](/static-files/83eebc1f-ae2b-472d-b1f7-f4024b6faf60) [0001193125-24-248083.rtf](/static-files/8c8fadc3-eca9-41ad-a864-4bc260cf143a) [0001193125-24-248083.xls](/static-files/27540e62-d276-4b07-93f7-6f6035d1fcae) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001193125-24-248083) [View HTML](/node/9026/html)  \nOct 29, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-118344) |  [0000950170-24-118344.pdf](/static-files/da6cbb62-6ea9-4b48-83d5-a084301194cf) [0000950170-24-118344.rtf](/static-files/c315a6f0-38ea-47be-9258-03d1bd18f227) [0000950170-24-118344.xls](/static-files/85b4e353-a07e-4150-b2fa-366af719097e) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-118344) [View HTML](/node/9001/html)  \nOct 29, 2024 | Quarterly report which provides a continuing view of a company's financial position | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-118366) |  [0000950170-24-118366.pdf](/static-files/8f552502-c763-40ce-b930-c3cc9c775090) [0000950170-24-118366.rtf](/static-files/1c2f5d0d-463a-4a58-b587-af29411440e5) [0000950170-24-118366.xls](/static-files/11abe8b9-ddd8-4eb0-bb6d-1a0bb569253f) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-118366) [View HTML](/node/9006/html)  \nOct 01, 2024 | Statement of changes in beneficial ownership of securities | [4](/sec-filings/sec-filing/4/0000950170-24-110858) |  [0000950170-24-110858.pdf](/static-files/80186e6e-420f-44e7-a099-6c290f4cc902) [0000950170-24-110858.rtf](/static-files/f5765cd4-3eff-4113-93d9-970bccda0b9c) [0000950170-24-110858.xls](/static-files/20f5b2a5-9a83-4947-83db-74b73edebccd) [View HTML](/node/8941/html)  \nSep 27, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0001193125-24-227940) |  [0001193125-24-227940.pdf](/static-files/6af7afbc-07ef-4597-ad1a-eb54d8615969) [0001193125-24-227940.rtf](/static-files/0bb35f9d-7020-4191-b629-e861d0134c1e) [0001193125-24-227940.xls](/static-files/6b1a1802-fe8e-4874-b839-5f45c72b5ce9) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001193125-24-227940) [View HTML](/node/8926/html)  \nJul 31, 2024 | Report of unscheduled material events or corporate event | [8-K](/sec-filings/sec-filing/8-k/0000950170-24-088581) |  [0000950170-24-088581.pdf](/static-files/a753668f-9a55-4aaf-b5b8-85c0fcdf9973) [0000950170-24-088581.rtf](/static-files/35fc1948-12bf-4bfc-a043-f4b6fa2ea14b) [0000950170-24-088581.xls](/static-files/44322a6c-667d-467a-8dbb-d4674b4d0b6d) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0000950170-24-088581) [View HTML](/node/8796/html)  \nJul 31, 2024 | Quarterly report which provides a continuing view of a company's financial position | [10-Q](/sec-filings/sec-filing/10-q/0000950170-24-088584) |  [0000950170-24-088584.pdf](/static-files/de4c616c-b932-449c-a44f-7a2e02770788) [0000950170-24-088584.rtf](/static-files/5cdb3e5b-93b4-4e69-b75d-fdce8d4d5cd5) [0000950170-24-088584.xls](/static-files/70305670-9ed1-4d2e-9639-1d390ebb6267) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0000950170-24-088584) [View HTML](/node/8801/html)  \nJul 18, 2024 | UPLOAD | [UPLOAD](/sec-filings/sec-filing/upload/0000000000-24-008181) |  [0000000000-24-008181.pdf](/static-files/8c42c9ad-ac42-42d1-9f31-14c8e671754f) [0000000000-24-008181.rtf](/static-files/a85c5766-b81f-49bd-9469-669ddd667558) [View HTML](/node/8876/html)  \nJul 10, 2024 | An amendment to the SC 13G filing | [SC 13G/A](/sec-filings/sec-filing/sc-13ga/0000093751-24-000656) |  [0000093751-24-000656.pdf](/static-files/6c159e43-c996-4002-af67-9a0cd9ee34a1) [0000093751-24-000656.rtf](/static-files/a34d02f0-24d6-4066-a4d7-eac25c097277) [View HTML](/node/8776/html)  \n  \nDisplaying 1 - 10 of 207 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        },
        {
          "title": "Annual Reports",
          "url": "https://investors.biomeafusion.com/financial-information/annual-reports",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  Annual Reports \n\n#  Annual Reports \n\n[Investor Menu](investors.html#)\n\n[![Annual Report for FY 2023](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2024/04/29/8-05-09/200x258_BMEA_10K_2024_V4-lowres.png?itok=8WdYj0Q2) ](/static-files/6b6182a8-cf1d-41de-8ea5-3be7003552a3)\n\n[Annual Report for FY 2023](/static-files/6b6182a8-cf1d-41de-8ea5-3be7003552a3 \"BMEA_10K_2024_V4-lowres.pdf\") 10.1 MB\n\n[![Annual Report for FY 2022](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2023/04/28/17-14-24/AR2022_200x258.png?itok=AkN64DGB) ](/static-files/fc496802-4a92-41ef-a482-c9217fe1ead9)\n\n[Annual Report for FY 2022](/static-files/fc496802-4a92-41ef-a482-c9217fe1ead9 \"Annual Report for FY 2022.pdf\") 5.7 MB\n\n[![2021 Annual Report](/system/files-encrypted/styles/nir_asset_small/encrypt/nasdaq_kms/assets/2022/05/03/13-42-32/BMEA_2021%20Annual%20Report%20Cover%20200x258.jpg?itok=_6NDnSYR) ](/static-files/52e254bc-54e8-4156-9847-fc82729f5f73)\n\n[Annual Report for FY 2021](/static-files/52e254bc-54e8-4156-9847-fc82729f5f73 \"BMEA_2021 Annual Report.pdf\") 17 MB\n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Governance Overview",
          "url": "https://investors.biomeafusion.com/corporate-governance/governance-overview",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  Corporate Governance \n\n#  Corporate Governance \n\n[Investor Menu](investors.html#)\n\n## Corporate Governance Overview\n\nBiomea Fusion is committed to maintaining high ethical standards in its business operations. The following documents describe these standards and the internal policies we have established to communicate and monitor them.\n\nCompliance Officer Contact: CorporateCompliance@biomeafusion.com\n\nGovernance Documents \n\n[Code of Business Conduct and Ethics](/static-files/43ecc185-ed20-4c81-ba1e-1e160bb71e06)\n\n[Guidelines for Corporate Disclosure](/static-files/be6a1760-91a9-47dc-825a-2a4fba794e5d)\n\nCommittee Charters \n\n[Nominating and Corporate Governance Committee Charter](/static-files/0f410f5c-4665-4f13-8ae0-b828893d6950)\n\n[Audit Committee Charter](/static-files/a6bd0fd3-9f6f-4927-9a79-806338ec0ee9)\n\n[Compensation Committee Charter](/static-files/3f29e14f-e5da-45b5-9844-20a98ba5f4cd)\n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        },
        {
          "title": "Committee Composition",
          "url": "https://investors.biomeafusion.com/corporate-governance/committee-composition",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![Biomea](/sites/g/files/knoqqb95546/themes/site/nir_pid4081/dist/wp-content/uploads/2020/11/Biomea-Fusion_Logo_RGB_rev2_Email-340x156-1.png)](https://biomeafusion.com/)\n\n#  Committee Composition \n\n#  Committee Composition \n\n[Investor Menu](investors.html#)\n\n[Audit Committee](/static-files/a6bd0fd3-9f6f-4927-9a79-806338ec0ee9) | [Compensation Committee](/static-files/3f29e14f-e5da-45b5-9844-20a98ba5f4cd) | [Nominating and Corporate Governance Committee](/static-files/0f410f5c-4665-4f13-8ae0-b828893d6950)  \n---|---|---  \nEric Aguiar, M.D.  |  [Audit Committee](/static-files/a6bd0fd3-9f6f-4927-9a79-806338ec0ee9) |  [Compensation Committee](/static-files/3f29e14f-e5da-45b5-9844-20a98ba5f4cd)  \nBihua Chen  |  [Compensation Committee](/static-files/3f29e14f-e5da-45b5-9844-20a98ba5f4cd) |  [Nominating and Corporate Governance Committee](/static-files/0f410f5c-4665-4f13-8ae0-b828893d6950)  \nElizabeth Faust, PhD  |  [Nominating and Corporate Governance Committee](/static-files/0f410f5c-4665-4f13-8ae0-b828893d6950)  \nMichael J.M. Hitchcock, Ph.D.  |  [Audit Committee](/static-files/a6bd0fd3-9f6f-4927-9a79-806338ec0ee9) |  [Compensation Committee](/static-files/3f29e14f-e5da-45b5-9844-20a98ba5f4cd) |  [Nominating and Corporate Governance Committee](/static-files/0f410f5c-4665-4f13-8ae0-b828893d6950)  \nSumita Ray, J.D.  |  [Audit Committee](/static-files/a6bd0fd3-9f6f-4927-9a79-806338ec0ee9) |  [Nominating and Corporate Governance Committee](/static-files/0f410f5c-4665-4f13-8ae0-b828893d6950)  \n  \n= Chairperson = Member\n\n[ Print Page]()\n\n[ Email Alerts](/ir-resources/email-alerts)\n\n[ RSS Feeds](/rss-feeds)\n\n[ Investor FAQs](/ir-resources/investor-faqs)\n\n[ Investor Contact](/ir-resources/investor-contact)\n\n  * [ admin-home ](https://biomeafusion.com/)\n  * [ info ](https://biomeafusion.com/about/)\n  * [ address-book ](https://biomeafusion.com/team/)\n  * [ medkit ](https://biomeafusion.com/science/)\n  * [ flask ](https://biomeafusion.com/pipeline/)\n  * [ briefcase ](https://biomeafusion.com/careers/)\n  * [ pressthis ](https://investors.biomeafusion.com/)\n  * [ map-signs ](https://biomeafusion.com/contact/)\n\n\n\n  * [ linkedin ](https://www.linkedin.com/company/biomeafusion)\n  * [ twitter ](https://twitter.com/biomeafusion)\n  * [ facebook ](https://www.facebook.com/biomeafusion)\n  * [ instagram ](https://www.instagram.com/biomeafusion/)\n  * mail\n\n\n\nCopyright 2020-2021 Biomea Fusion, Inc. All Rights Reserved. [Privacy Policy](https://biomeafusion.com/privacy-policy/) | [Terms of Service](https://biomeafusion.com/terms-of-service/)\n\n[Scroll to top](#top \"Scroll to top\")\n"
        }
      ]
    }
  ]
}